Form 4: Mineralys Director Gold Receives Equity Grants

Mineralys Therapeutics, Inc. director Alexander M. Gold was granted 6,200 Restricted Stock Units and options for 8,300 shares of common stock.

Summary

• Alexander M. Gold, a Director of Mineralys Therapeutics, Inc. (MLYS), was granted 6,200 Restricted Stock Units (RSUs) on February 19, 2026.
• Each RSU represents a contingent right to receive one share of common stock upon vesting, which occurs in one annual installment following the grant date.
• Additionally, Mr. Gold was granted stock options for 8,300 shares of common stock on February 19, 2026, with an exercise price of $28.06 per share.
• These stock options vest in 12 substantially equal monthly installments following the grant date and have an expiration date of February 19, 2036.
• Following these transactions, Mr. Gold beneficially owns 6,200 shares of common stock (from RSUs) and 8,300 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting standard director compensation practices that align management interests with shareholders, without indicating any significant operational or financial changes.

Positives

• The equity grants align the interests of Director Alexander M. Gold with those of shareholders, incentivizing long-term performance.
• The grants represent a standard form of compensation for directors, indicating continued commitment to attracting and retaining qualified board members.

Risks

• The value of the granted RSUs and stock options is subject to the future performance of Mineralys Therapeutics, Inc.'s common stock, posing market risk to the recipient.

Future Outlook

The filing details future vesting schedules for the granted equity, with RSUs vesting in one annual installment and stock options vesting in 12 equal monthly installments following the February 19, 2026 grant date.

Industry Context

StockSavvy.ai notes that equity compensation, including Restricted Stock Units and stock options, is a prevalent practice across the biotechnology and pharmaceutical industries for executive and director remuneration. This approach is designed to align leadership incentives with long-term shareholder value creation, a common strategy in sectors requiring significant R&D investment and long product development cycles.

Comparison to Industry Standards

• The structure of equity grants, combining RSUs and stock options with multi-year vesting, is consistent with compensation practices observed in comparable biopharmaceutical companies such as Mirati Therapeutics (MRTX) or Blueprint Medicines (BPMC), where similar mechanisms are used to retain talent and incentivize performance over several years.
• The exercise price of $28.06 for the stock options is typical, being set at the market price on the grant date, which is a standard practice for incentive stock options in the U.S. market.

Related Party Transactions

• The grant of 6,200 Restricted Stock Units and 8,300 stock options to Alexander M. Gold, a Director of Mineralys Therapeutics, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The equity grants are intended to align the director's interests with shareholders, potentially leading to better long-term performance and value creation.
• Employees: No direct impact on general employees is indicated by this specific filing, though it reflects the company's overall compensation philosophy for leadership.

Next Steps

• The 6,200 Restricted Stock Units will vest in one annual installment following the grant date of February 19, 2026.
• The 8,300 stock options will vest in 12 substantially equal monthly installments following the grant date of February 19, 2026.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a director, which is a standard compensation practice and does not provide new material information that would significantly alter the investment thesis for Mineralys Therapeutics, Inc. It reinforces alignment of interests but does not indicate a change in company fundamentals or outlook, thus a 'hold' recommendation is appropriate for existing investors.

Keywords

Mineralys Therapeutics, MLYS, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Director Compensation, Equity Grant